Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets.


Journal

Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354

Informations de publication

Date de publication:
09 2023
Historique:
received: 22 03 2023
accepted: 13 07 2023
medline: 28 8 2023
pubmed: 11 8 2023
entrez: 10 8 2023
Statut: ppublish

Résumé

Circulating proteins have important functions in inflammation and a broad range of diseases. To identify genetic influences on inflammation-related proteins, we conducted a genome-wide protein quantitative trait locus (pQTL) study of 91 plasma proteins measured using the Olink Target platform in 14,824 participants. We identified 180 pQTLs (59 cis, 121 trans). Integration of pQTL data with eQTL and disease genome-wide association studies provided insight into pathogenesis, implicating lymphotoxin-α in multiple sclerosis. Using Mendelian randomization (MR) to assess causality in disease etiology, we identified both shared and distinct effects of specific proteins across immune-mediated diseases, including directionally discordant effects of CD40 on risk of rheumatoid arthritis versus multiple sclerosis and inflammatory bowel disease. MR implicated CXCL5 in the etiology of ulcerative colitis (UC) and we show elevated gut CXCL5 transcript expression in patients with UC. These results identify targets of existing drugs and provide a powerful resource to facilitate future drug target prioritization.

Identifiants

pubmed: 37563310
doi: 10.1038/s41590-023-01588-w
pii: 10.1038/s41590-023-01588-w
pmc: PMC10457199
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1540-1551

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Investigateurs

Andres Metspalu (A)
Lili Milani (L)
Reedik Mägi (R)
Mari Nelis (M)
Georgi Hudjašov (G)

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2023. The Author(s).

Références

Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 (2018).
pubmed: 29875488 pmcid: 6697541 doi: 10.1038/s41586-018-0175-2
Enroth, S., Johansson, A., Enroth, S. B. & Gyllensten, U. Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs. Nat. Commun. 5, 4684 (2014).
pubmed: 25147954 doi: 10.1038/ncomms5684
Suhre, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat. Commun. 8, 14357 (2017).
pubmed: 28240269 pmcid: 5333359 doi: 10.1038/ncomms14357
Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769–773 (2018).
pubmed: 30072576 pmcid: 6190714 doi: 10.1126/science.aaq1327
Melzer, D. et al. A genome-wide association study identifies protein quantitative trait loci (pQTLs). PLoS Genet. 4, e1000072 (2008).
pubmed: 18464913 pmcid: 2362067 doi: 10.1371/journal.pgen.1000072
Lourdusamy, A. et al. Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum. Mol. Genet. 21, 3719–3726 (2012).
pubmed: 22595970 pmcid: 6446535 doi: 10.1093/hmg/dds186
Folkersen, L. et al. Genomic and drug target evaluation of 90 cardiovascular proteins in 30,931 individuals. Nat. Metab. 2, 1135–1148 (2020).
pubmed: 33067605 pmcid: 7611474 doi: 10.1038/s42255-020-00287-2
Pietzner, M. et al. Mapping the proteo-genomic convergence of human diseases. Science 374, eabj1541 (2021).
pubmed: 34648354 pmcid: 9904207 doi: 10.1126/science.abj1541
Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics and disease. Nat. Genet. 53, 1712–1721 (2021).
pubmed: 34857953 doi: 10.1038/s41588-021-00978-w
Zhang, J. et al. Plasma proteome analyses in individuals of European and African ancestry identify cis-pQTLs and models for proteome-wide association studies. Nat. Genet. 54, 593–602 (2022).
pubmed: 35501419 pmcid: 9236177 doi: 10.1038/s41588-022-01051-w
Gudjonsson, A. et al. A genome-wide association study of serum proteins reveals shared loci with common diseases. Nat. Commun. 13, 480 (2022).
pubmed: 35078996 pmcid: 8789779 doi: 10.1038/s41467-021-27850-z
Siegbahn, A. et al. Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. J. Thromb. Haemost. 19, 2726–2737 (2021).
pubmed: 34390530 doi: 10.1111/jth.15498
Pietzner, M. et al. Synergistic insights into human health from aptamer- and antibody-based proteomic profiling. Nat. Commun. 12, 6822 (2021).
pubmed: 34819519 pmcid: 8613205 doi: 10.1038/s41467-021-27164-0
Võsa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. Nat. Genet. 53, 1300–1310 (2021).
pubmed: 34475573 pmcid: 8432599 doi: 10.1038/s41588-021-00913-z
The GTEx Consortium et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).
pmcid: 7737656 doi: 10.1126/science.aaz1776
Peters, J. E. et al. Insight into genotype–phenotype associations through eQTL mapping in multiple cell types in health and immune-mediated disease. PLoS Genet. 12, e1005908 (2016).
pubmed: 27015630 pmcid: 4807835 doi: 10.1371/journal.pgen.1005908
Kerimov, N. et al. A compendium of uniformly processed human gene expression and splicing quantitative trait loci. Nat. Genet. 53, 1290–1299 (2021).
pubmed: 34493866 pmcid: 8423625 doi: 10.1038/s41588-021-00924-w
Stacey, D. et al. ProGeM: a framework for the prioritization of candidate causal genes at molecular quantitative trait loci. Nucleic Acids Res. 47, e3 (2019).
pubmed: 30239796 doi: 10.1093/nar/gky837
Rappoport, N., Simon, A. J., Amariglio, N. & Rechavi, G. The Duffy antigen receptor for chemokines, ACKR1, ‘Jeanne DARC’ of benign neutropenia. Br. J. Haematol. 184, 497–507 (2019).
pubmed: 30592023 doi: 10.1111/bjh.15730
Chen, M.-H. et al. Trans-ethnic and ancestry-specific blood-cell genetics in 746,667 individuals from 5 global populations. Cell 182, 1198–1213.e1114 (2020).
pubmed: 32888493 pmcid: 7480402 doi: 10.1016/j.cell.2020.06.045
Hassan, H. T. & Zander, A. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis. Acta Haematol. 95, 257–262 (1996).
pubmed: 8677752 doi: 10.1159/000203893
Claussnitzer, M. et al. A brief history of human disease genetics. Nature 577, 179–189 (2020).
pubmed: 31915397 pmcid: 7405896 doi: 10.1038/s41586-019-1879-7
Ferreira, R. C. et al. Functional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseases. PLoS Genet. 9, e1003444 (2013).
pubmed: 23593036 pmcid: 3617094 doi: 10.1371/journal.pgen.1003444
Rosa, M. et al. A Mendelian randomization study of IL6 signaling in cardiovascular diseases, immune-related disorders and longevity. NPJ Genom. Med 4, 23 (2019).
pubmed: 31552141 pmcid: 6754413 doi: 10.1038/s41525-019-0097-4
Patsopoulos, A. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science 365, eaav7188 (2019).
doi: 10.1126/science.aav7188
Gregory, A. P. et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488, 508–511 (2012).
pubmed: 22801493 pmcid: 4268493 doi: 10.1038/nature11307
Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1–22 (2003).
pubmed: 12689998 doi: 10.1093/ije/dyg070
Zhu, Z. et al. Causal associations between risk factors and common diseases inferred from GWAS summary data. Nat. Commun. 9, 224 (2018).
pubmed: 29335400 pmcid: 5768719 doi: 10.1038/s41467-017-02317-2
Massimino, L. et al. The inflammatory bowel disease transcriptome and metatranscriptome meta-analysis (IBD TaMMA) framework. Nat. Computat. Sci. 1, 511–515 (2021).
doi: 10.1038/s43588-021-00114-y
Croft, M. & Siegel, R. M. Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases. Nat. Rev. Rheumatol. 13, 217–233 (2017).
pubmed: 28275260 pmcid: 5486401 doi: 10.1038/nrrheum.2017.22
Yasuda, H. Discovery of the RANKL/RANK/OPG system. J. Bone Min. Metab. 39, 2–11 (2021).
doi: 10.1007/s00774-020-01175-1
Walsh, M. C. & Choi, Y. Biology of the RANKL-RANK-OPG system in immunity, bone, and beyond. Front. Immunol. 5, 511 (2014).
pubmed: 25368616 pmcid: 4202272 doi: 10.3389/fimmu.2014.00511
Jakubowski, A. et al. Dual role for TWEAK in angiogenic regulation. J. Cell Sci. 115, 267–274 (2002).
pubmed: 11839778 doi: 10.1242/jcs.115.2.267
Donohue, P. J. et al. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler. Thromb. Vasc. Biol. 23, 594–600 (2003).
pubmed: 12615668 doi: 10.1161/01.ATV.0000062883.93715.37
Domouzoglou, E. M. et al. Fibroblast growth factors in cardiovascular disease: the emerging role of FGF21. Am. J. Physiol. Heart Circ. Physiol. 309, H1029–H1038 (2015).
pubmed: 26232236 pmcid: 4747916 doi: 10.1152/ajpheart.00527.2015
Schett, G., McInnes, I. B. & Neurath, M. F. Reframing immune-mediated inflammatory diseases through signature cytokine hubs. N. Engl. J. Med. 385, 628–639 (2021).
pubmed: 34379924 doi: 10.1056/NEJMra1909094
Peters, A. L., Stunz, L. L. & Bishop, G. A. CD40 and autoimmunity: the dark side of a great activator. Semin. Immunol. 21, 293–300 (2009).
pubmed: 19595612 pmcid: 2753170 doi: 10.1016/j.smim.2009.05.012
Durie, F. H. et al. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261, 1328–1330 (1993).
pubmed: 7689748 doi: 10.1126/science.7689748
Guo, Y. et al. CD40L-dependent pathway is active at various stages of rheumatoid arthritis disease progression. J. Immunol. 198, 4490–4501 (2017).
pubmed: 28455435 doi: 10.4049/jimmunol.1601988
The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 457–465 (1999).
doi: 10.1212/WNL.53.3.457
Bosch, X., Saiz, A., Ramos-Casals, M. & Group, B. S. Monoclonal antibody therapy-associated neurological disorders. Nat. Rev. Neurol. 7, 165–172 (2011).
pubmed: 21263460 doi: 10.1038/nrneurol.2011.1
Singh, U. P. et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine 77, 44–49 (2016).
pubmed: 26520877 doi: 10.1016/j.cyto.2015.10.008
Friedrich, M. et al. IL-1-driven stromal-neutrophil interactions define a subset of patients with inflammatory bowel disease that does not respond to therapies. Nat. Med. 27, 1970–1981 (2021).
pubmed: 34675383 pmcid: 8604730 doi: 10.1038/s41591-021-01520-5
Pavlidis, P. et al. Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapy. Nat. Commun. 13, 5820 (2022).
pubmed: 36192482 pmcid: 9530232 doi: 10.1038/s41467-022-33331-8
Richard, A. C. et al. Reduced monocyte and macrophage TNFSF15/TL1A expression is associated with susceptibility to inflammatory bowel disease. PLoS Genet. 14, e1007458 (2018).
pubmed: 30199539 pmcid: 6130856 doi: 10.1371/journal.pgen.1007458
Bamias, G. et al. Differential expression of the TL1A/DcR3 system of TNF/TNFR-like proteins in large vs. small intestinal Crohn’s disease. Dig. Liver Dis. 44, 30–36 (2012).
pubmed: 21978578 doi: 10.1016/j.dld.2011.09.002
Bamias, G. et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin. Immunol. 137, 242–249 (2010).
pubmed: 20675196 doi: 10.1016/j.clim.2010.07.001
Sands, B. et al. PRA023 demonstrated efficacy and favorable safety as induction therapy for moderately to severely active UC: phase 2 ARTEMIS-UC study results. European Crohn’s and Colitis Organisation https://www.ecco-ibd.eu/publications/congress-abstracts/item/op40-pra023-demonstrated-efficacy-and-favorable-safety-as-induction-therapy-for-moderately-to-severely-active-uc-phase-2-artemis-uc-study-results.html (2023).
Fairfax, B. P. et al. Innate immune activity conditions the effect of regulatory variants upon monocyte gene expression. Science 343, 1246949 (2014).
pubmed: 24604202 pmcid: 4064786 doi: 10.1126/science.1246949
Lee, M. N. et al. Common genetic variants modulate pathogen-sensing responses in human dendritic cells. Science 343, 1246980 (2014).
pubmed: 24604203 pmcid: 4124741 doi: 10.1126/science.1246980
de Lange, K. M. et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. Nat. Genet. 49, 256–261 (2017).
pubmed: 28067908 pmcid: 5289481 doi: 10.1038/ng.3760
Hijazi, Z. et al. Screening of multiple biomarkers associated with ischemic stroke in atrial fibrillation. J. Am. Heart Assoc. 9, e018984 (2020).
pubmed: 33292046 pmcid: 7955358 doi: 10.1161/JAHA.120.018984
Sanna, S. et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat. Genet. 51, 600–605 (2019).
pubmed: 30778224 pmcid: 6441384 doi: 10.1038/s41588-019-0350-x
Yang, J. et al. Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. Nat. Genet. 44, 369–375 (2012).
pubmed: 22426310 pmcid: 3593158 doi: 10.1038/ng.2213
Winter, D. J. rentrez: an R package for the NCBI eUtils API. R Journal 9, 520–526 (2017).
doi: 10.32614/RJ-2017-058
Kamat, M. A. et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics 35, 4851–4853 (2019).
pubmed: 31233103 pmcid: 6853652 doi: 10.1093/bioinformatics/btz469
McLean, C. Y. et al. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 28, 495–501 (2010).
pubmed: 20436461 pmcid: 4840234 doi: 10.1038/nbt.1630
Zhu, Z. et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat. Genet. 48, 481–487 (2016).
pubmed: 27019110 doi: 10.1038/ng.3538
Ochoa, D. et al. Open Targets Platform: supporting systematic drug-target identification and prioritisation. Nucleic Acids Res. 49, D1302–D1310 (2021).
pubmed: 33196847 doi: 10.1093/nar/gkaa1027
Foley, C. N. et al. A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits. Nat. Commun. 12, 764 (2021).
pubmed: 33536417 pmcid: 7858636 doi: 10.1038/s41467-020-20885-8
Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat. Genet. 52, 1122–1131 (2020).
pubmed: 32895551 pmcid: 7610464 doi: 10.1038/s41588-020-0682-6
Robinson, J. W. et al. An efficient and robust tool for colocalisation: pair-wise conditional and colocalisation (PWCoCo). Preprint at bioRxiv https://doi.org/2022.2008.2008.503158 (2022).
Arijs, I. et al. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS ONE 4, e7984 (2009).
pubmed: 19956723 pmcid: 2776509 doi: 10.1371/journal.pone.0007984
Sands, B. E. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 381, 1201–1214 (2019).
pubmed: 31553833 doi: 10.1056/NEJMoa1900750
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
pubmed: 24695404 pmcid: 4103590 doi: 10.1093/bioinformatics/btu170
Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. Methods 12, 357–360 (2015).
pubmed: 25751142 pmcid: 4655817 doi: 10.1038/nmeth.3317
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700 doi: 10.1093/bioinformatics/btu638

Auteurs

Jing Hua Zhao (JH)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.

David Stacey (D)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
Australian Centre for Precision Health, Unit of Clinical and Health Sciences, University of South Australia, Adelaide, South Australia, Australia.
South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.

Niclas Eriksson (N)

Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Erin Macdonald-Dunlop (E)

Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, UK.

Åsa K Hedman (ÅK)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Development and Medical, Pfizer Worldwide Research, Stockholm, Sweden.

Anette Kalnapenkis (A)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.

Stefan Enroth (S)

Department of Immunology, Genetics, and Pathology, Biomedical Center, SciLifeLab Uppsala, Uppsala University, Uppsala, Sweden.

Domenico Cozzetto (D)

Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.

Jonathan Digby-Bell (J)

School of Immunology and Microbial Sciences, King's College London, London, UK.

Jonathan Marten (J)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

Lasse Folkersen (L)

Nucleus Genomics ltd, New York, NY, USA.

Christian Herder (C)

Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany.
Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
German Center for Diabetes Research, Munich-Neuherberg, Germany.

Lina Jonsson (L)

Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.

Sarah E Bergen (SE)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.

Christian Gieger (C)

Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

Elise J Needham (EJ)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.

Praveen Surendran (P)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
British Heart Foundation Centre of Research Excellence, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Health Data Research UK, Wellcome Genome Campus and University of Cambridge, Hinxton, UK.

Dirk S Paul (DS)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
British Heart Foundation Centre of Research Excellence, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.

Ozren Polasek (O)

Medical School, University of Split, Split, Croatia.

Barbara Thorand (B)

German Center for Diabetes Research, Munich-Neuherberg, Germany.
Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

Harald Grallert (H)

German Center for Diabetes Research, Munich-Neuherberg, Germany.
Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.
Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany.

Michael Roden (M)

Institute for Clinical Diabetology, German Diabetes Center, Düsseldorf, Germany.
Department of Endocrinology and Diabetology, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
German Center for Diabetes Research, Munich-Neuherberg, Germany.

Urmo Võsa (U)

Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.

Tonu Esko (T)

Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia.

Caroline Hayward (C)

MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.

Åsa Johansson (Å)

Department of Immunology, Genetics, and Pathology, Biomedical Center, SciLifeLab Uppsala, Uppsala University, Uppsala, Sweden.

Ulf Gyllensten (U)

Department of Immunology, Genetics, and Pathology, Biomedical Center, SciLifeLab Uppsala, Uppsala University, Uppsala, Sweden.

Nick Powell (N)

Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK.

Oskar Hansson (O)

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.
Skåne University Hospital, Malmö, Sweden.

Niklas Mattsson-Carlgren (N)

Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden.
Clinical Memory Research Unit, Faculty of Medicine, Lund University, Lund, Sweden.
Department of Neurology, Skåne University Hospital, Lund University, Lund, Sweden.

Peter K Joshi (PK)

Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, UK.

John Danesh (J)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.
Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK.
British Heart Foundation Centre of Research Excellence, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Health Data Research UK, Wellcome Genome Campus and University of Cambridge, Hinxton, UK.
NIHR Blood and Transplant Research Unit in Donor Health and Behaviour, University of Cambridge, Cambridge, UK.
Department of Human Genetics, Wellcome Sanger Institute, Hinxton, UK.

Leonid Padyukov (L)

Division of Rheumatology, Department of Medicine (Solna), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Lars Klareskog (L)

Division of Rheumatology, Department of Medicine (Solna), Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.

Mikael Landén (M)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Institute of Neuroscience and Physiology, University of Gothenburg, Gothenburg, Sweden.

James F Wilson (JF)

Centre for Global Health Research, Usher Institute, University of Edinburgh, Edinburgh, UK.
MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital, Edinburgh, UK.

Agneta Siegbahn (A)

Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Lars Wallentin (L)

Department of Medical Sciences and Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden.

Anders Mälarstig (A)

Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Development and Medical, Pfizer Worldwide Research, Stockholm, Sweden.

Adam S Butterworth (AS)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. asb38@medschl.cam.ac.uk.
Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge, UK. asb38@medschl.cam.ac.uk.
British Heart Foundation Centre of Research Excellence, School of Clinical Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK. asb38@medschl.cam.ac.uk.
Health Data Research UK, Wellcome Genome Campus and University of Cambridge, Hinxton, UK. asb38@medschl.cam.ac.uk.
NIHR Blood and Transplant Research Unit in Donor Health and Behaviour, University of Cambridge, Cambridge, UK. asb38@medschl.cam.ac.uk.

James E Peters (JE)

British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK. j.peters@imperial.ac.uk.
Health Data Research UK, Wellcome Genome Campus and University of Cambridge, Hinxton, UK. j.peters@imperial.ac.uk.
Department of Immunology and Inflammation, Imperial College London, London, UK. j.peters@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH